This article is more than 5 years old. Information may no longer be current.
Recent highlights, research on ATX-101 for submental fullness
Although ATX-101 has yet to be FDA approved, the buzz has strengthened for this submental fullness injectable from Kythera.
Click the links below to read more on the latest research updates from clinical investigators and In the Journals news on ATX-101 (deoxycholic acid).
FDA advisory panel recommends approval of deoxycholic acid injection for submental fat reduction
The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted 17-0 in favor of new drug application 206333 submitted by Kythera Biopharmaceuticals for injectable 1% deoxycholic acid (DCA), also referred to as ATX-101, for subcutaneous use. Read more.
VIDEO: Tina Alster , MD: ATX-101 effective at removing submental fat
“There’s been nothing else available that is noninvasive where you can get rid of this fat,” Tina Alster, MD, told Healio.com/Dermatology at the American Academy of Dermatology meeting. Watch video.
Subcutaneous injection of ATX-101 offers favorable safety, pharmacokinetic profiles
Researchers found subcutaneous injection of ATX-101 for the reduction of submental fat offered favorable safety and pharmacokinetic profiles, with no clinically meaningful changes in deoxycholic acid, lipids and proinflammatory cytokines. Read more.
VIDEO: Mary Lupo , MD, FAAD, discusses potential use of ATX-101 to treat ‘ double chin ’
“This product is going to be a first-in-kind injectable,” Mary Lupo, MD, FAAD, told Healio.com/Dermatology. “In my experience, this product has a place, especially in patients who have localized fat pockets in this area. I would suggest that one should stay on-label with this product and use it as it is intended, which is a very defined grid in the neck below the jawline.” Watch video.
VIDEO: Researcher Shannon Humphrey, MD, discusses ATX-101
SAN FRANCISCO - In this video, Shannon Humphrey, MD, a dermatologist and clinical assistant professor at the University of British Columbia, discusses the potential of ATX-101, a deoxycholic acid injection, for treating submental fat. Watch video.